{"id":11816,"date":"2026-01-28T00:07:24","date_gmt":"2026-01-28T00:07:24","guid":{"rendered":"https:\/\/diyhaven858.wasmer.app\/index.php\/fda-clears-investigational-new-drug-application-for-nov05\/"},"modified":"2026-01-28T00:07:24","modified_gmt":"2026-01-28T00:07:24","slug":"fda-clears-investigational-new-drug-application-for-nov05","status":"publish","type":"post","link":"https:\/\/diyhaven858.wasmer.app\/index.php\/fda-clears-investigational-new-drug-application-for-nov05\/","title":{"rendered":"FDA clears investigational new drug application for NOV05"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div>\n<div class=\"img-group\">\n<img decoding=\"async\" class=\"perspective-img\" src=\"https:\/\/www.healio.com\/~\/media\/slack-news\/ophthalmology\/mugs\/d\/deaner_jordan-80x106.jpg?w=79\" alt=\"Jordan D. Deaner, MD\"\/>\n<\/div>\n<p>The FDA\u2019s clearance of the investigational new drug (IND) application to advance NOV05 in a phase 2 clinical trial for noninfectious anterior uveitis (NIAU) represents a meaningful advance in the uveitis treatment landscape.\u00a0<\/p>\n<p>Currently, corticosteroids remain the gold standard for the treatment of NIAU, but these therapies have well-recognized complications including cataract and elevated IOP. In patients with chronic disease or in whom corticosteroid-related adverse effects need to be avoided, systemic steroid-sparing immunosuppression is often employed, but its use may be limited by systemic tolerability. NOV05 is a corticosteroid-free topical tacrolimus formulation that aims to deliver effective anti-inflammatory therapy to eyes with NIAU, potentially mitigating the risks associated with topical, periocular or intraocular corticosteroids or systemic immunosuppression.<\/p>\n<p>Effective well-tolerated corticosteroid-sparing therapies for anterior uveitis remain an important unmet need, and this IND clearance establishes a critical step toward expanding locally delivered treatment options for ophthalmologists.<\/p>\n<div class=\"affiliation\">\n<p>Jordan D. Deaner, MD<\/p>\n<p>Mid Atlantic Retina<\/p>\n<p>Retina Service, Wills Eye Hospital<\/p>\n<p>Assistant professor of ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University <\/p>\n<\/div>\n<p>\n<strong>Disclosures: <\/strong> Deaner reports consulting for AbbVie, ANI Pharmaceuticals, Bausch + Lomb, EyePoint Pharmaceuticals, Genentech and Regeneron and speaking for ANI Pharmaceuticals and Bausch + Lomb.\n<\/p>\n<\/div>\n<p><br \/>\n<br \/><<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA\u2019s clearance of the investigational new drug (IND) application to advance NOV05 in a phase 2 clinical trial for noninfectious anterior uveitis (NIAU) represents a meaningful advance in the uveitis treatment landscape.\u00a0 Currently, corticosteroids remain the gold standard for the treatment of NIAU, but these therapies have well-recognized complications including cataract and elevated IOP. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":11817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-11816","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/01\/deaner_jordan-80x106.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/11816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=11816"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/11816\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/11817"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=11816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=11816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=11816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}